Pre-clinical

Ebixa is a moderate affinity, uncompetitive NMDA receptor antagonist.

In this section you can explore the unique features of Ebixa. Click on the list below to read more.

Mechanism of action of memantine
Johnson JW, Kotermanski SE Curr Opin Pharmacol 2006; 6(1):61-67

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration
Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. FEBS Letters 566 (2004) 261–269

Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer disease
Paul T. Francis

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease
Rogawski MA, Wenk GL,. CNS Drug Rev 2003; 9(3):275-308

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease:preclinical evidence
Danysz W, Parsons CG. Int J Ger Psychiatry 2003; 18: S23-S32

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse
Parsons CG, Stöffler A, Danysz W., Neuropharmacology. 2007 Nov;53(6):699-723. Epub 2007 Aug 10